1.65
+0.05(+3.13%)
Currency In USD
Address
1951 NW 7th Avenue
Miami, FL 33136
United States of America
Phone
305 909 0840
Website
Sector
Healthcare
Industry
Biotechnology
Employees
23
First IPO Date
February 12, 2021
| Name | Title | Pay | Year Born |
| Mr. Mohamed Wa'el Ahmed Hashad M.B.A. | Chief Executive Officer & Director | 867,854 | 1962 |
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer & Chairman | 74,000 | 1963 |
| Ms. Lisa A. Locklear M.B.A. | Chief Financial Officer & Treasurer | 472,272 | 1961 |
| Mr. Paul T. Lehr J.D. | International Executive Director, General Counsel & Secretary | 554,055 | 1968 |
| Mr. Michael Mannarino | Vice President & Corporate Controller | 0 | N/A |
| Dr. Dan Gincel Ph.D. | Senior Vice President of Strategic Collaborations & Scientific Affairs | 0 | 1971 |
| Ms. Elly Ryu | Vice President & Corporate Controller | 0 | 1981 |
| Dr. Nataliya Agafonova M.D. | Chief Medical Officer | 0 | 1969 |
| Ms. Lisa McClain-Moss | Vice President of Manufacturing | 0 | 1971 |
| Mr. Brian G Rash Ph.D. | Vice President of Research & Discovery | 0 | N/A |
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.